Navidea Biopharmaceuticals Inc Price/Sales
Cos'è Price/Sales di Navidea Biopharmaceuticals Inc?
Price/Sales di Navidea Biopharmaceuticals Inc è 1,194.84
Qual è la definizione di Price/Sales?
Il rapporto prezzo / vendite è il prezzo delle azioni di una società rispetto ai suoi ricavi.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Price/Sales di aziende nel Health Care settore su NYSEMKT rispetto a Navidea Biopharmaceuticals Inc
Cosa fa Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Aziende con price/sales simili a Navidea Biopharmaceuticals Inc
- Blueone Card Inc ha Price/Sales di 1,164.31
- PanTerra Gold ha Price/Sales di 1,165.06
- Chimerix Inc ha Price/Sales di 1,170.88
- CytoDyn ha Price/Sales di 1,174.39
- Cellular Biomedicine Inc ha Price/Sales di 1,184.26
- Black Rock Mining ha Price/Sales di 1,188.66
- Navidea Biopharmaceuticals Inc ha Price/Sales di 1,194.84
- Kraig Biocraft Laboratories ha Price/Sales di 1,199.03
- Buderim ha Price/Sales di 1,206.67
- NeuroVive Pharmaceutical AB ha Price/Sales di 1,207.19
- Strategic Elements Ltd ha Price/Sales di 1,216.32
- Greenland Minerals ha Price/Sales di 1,251.46
- Galantas Gold ha Price/Sales di 1,271.42